NUZ-001
PreclinicalSmall molecule
NUZ-001 is one of 45 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Preclinical.
2
Indications
2
Total Trials
2
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Amyotrophic Lateral Sclerosis
#DrugCompanyPhaseTrials
1Nourianz
Kyowa Kirin Co., Ltd.Approved
Vimpat
UCBApproved
Enablex
AbbVieApproved
Bosulif
PPrism Pharmaceuticals
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Quinidine Gluconate
WWyeth-Lederle Vaccines
Approved
Transderm Scop
BBaxter Healthcare Corporation
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Atropen
FFresenius Kabi Taiwan Ltd.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NUZ-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMerit E. Cudkowicz, MD